Lawrence Fleckenstein
Overview
Explore the profile of Lawrence Fleckenstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
991
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramharter M, Djimde A, Borghini-Fuhrer I, Miller R, Shin J, Aspinall A, et al.
Malar J
. 2024 Feb;
23(1):61.
PMID: 38418982
Background: Children are particularly at risk of malaria. This analysis consolidates the clinical data for pyronaridine-artesunate (PA) paediatric granules in children from three randomized clinical trials and a real-world study...
2.
Fleckenstein L, Miller R
J Clin Pharmacol
. 2022 Jun;
62(10):1321-1322.
PMID: 35726879
No abstract available.
3.
Tan B, Opoku N, Attah S, Awadzi K, Kuesel A, Lazdins-Helds J, et al.
PLoS Negl Trop Dis
. 2022 Mar;
16(3):e0010005.
PMID: 35333880
Background: Onchocerciasis ("river blindness"), is a neglected tropical disease caused by the filarial nematode Onchocerca volvulus and transmitted to humans through repeated bites by infective blackflies of the genus Simulium....
4.
Korth-Bradley J, Parks V, Patat A, Matschke K, Mayer P, Fleckenstein L
Clin Pharmacol Drug Dev
. 2016 May;
1(1):32-7.
PMID: 27206144
The antiparasitic agent moxidectin is under development for the treatment of onchocerciasis. As the first-in-human study of moxidectin used a liquid formulation but other trials used tablets, a study was...
5.
Korth-Bradley J, Parks V, Wagner F, Chalon S, Gourley I, Matschke K, et al.
Clin Pharmacol Drug Dev
. 2016 Apr;
3(2):151-7.
PMID: 27128460
In order to evaluate the potential for CYP3A4 induction by moxidectin, midazolam pharmacokinetic (PK) parameters were compared before and after moxidectin administration. Healthy subjects received a single 8 mg dose...
6.
Ayyoub A, Methaneethorn J, Ramharter M, Djimde A, Tekete M, Duparc S, et al.
Antimicrob Agents Chemother
. 2015 Dec;
60(3):1450-8.
PMID: 26666916
Pyramax is a pyronaridine (PYR)-artesunate (PA) combination for the treatment of uncomplicated malaria in adult and pediatric patients. A granule formulation of this combination is being developed for treatment of...
7.
Bogoch I, Khan K, Abrams H, Nott C, Leung E, Fleckenstein L, et al.
Am J Trop Med Hyg
. 2015 Apr;
93(1):94-6.
PMID: 25918215
Two cases of Strongyloides hyperinfection are presented. Ivermectin was initially administered orally and per rectum pending the availability of subcutaneous (SC) preparations. In neither case did rectal suppositories of ivermectin...
8.
Ouedraogo A, Bastiaens G, Tiono A, Guelbeogo W, Kobylinski K, Ouedraogo A, et al.
Clin Infect Dis
. 2014 Nov;
60(3):357-65.
PMID: 25414262
Background: Artemisinin combination therapy effectively clears asexual malaria parasites and immature gametocytes but does not prevent posttreatment malaria transmission. Ivermectin (IVM) may reduce malaria transmission by killing mosquitoes that take...
9.
Morris C, Pokorny R, Lopez-Lazaro L, Miller R, Arbe-Barnes S, Duparc S, et al.
Antimicrob Agents Chemother
. 2014 Jul;
58(10):5900-8.
PMID: 25070091
The objectives of this study were to characterize any drug-drug interaction between the antimalarial Pyramax (pyronaridine-artesunate [PA]) and the CYP2D6 probe substrate metoprolol and to assess the safety of 60-day...
10.
Schmidt M, King C, Thomsen E, Siba P, Sanuku N, Fleckenstein L
J Pharm Biomed Anal
. 2014 Jul;
98:307-10.
PMID: 24975211
A sensitive and selective liquid chromatographic method using mass spectrometric detection was developed for the determination of diethylcarbamazine (DEC) in human plasma. DEC and its stable isotope internal standard d3-DEC...